Paul A Goepfert MD
Professor, Medicine, University of Alabama School of Medicine
Join to View Full Profile
619 19th St SBirmingham, AL 35233
Phone+1 205-934-6600
Dr. Goepfert is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Alabama Medical CenterFellowship, Infectious Disease, 1994 - 1997- University of Alabama Medical CenterResidency, Internal Medicine, 1991 - 1994
Baylor College of MedicineClass of 1991
Certifications & Licensure
AL State Medical License 1992 - 2025
TX State Medical License 1992 - 1997
American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2010
Clinical Trials
- Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults
- Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth Start of enrollment: 2002 Dec 01
- Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults Start of enrollment: 2006 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell respo...Zoe Moodie, Shuying Sue Li, Elena E Giorgi, LaTonya D Williams, One Dintwe
Emerging Microbes & Infections. 2025-12-01 - 3 citations2024 Update of the RECOVER-Adult Long COVID Research Index.Linda N Geng, Kristine M Erlandson, Mady Hornig, Rebecca Letts, Caitlin Selvaggi
JAMA. 2025-02-25 - Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59®.Sharon E Frey, Rebecca Brady, Lisa Jackson, Paul Goepfert, Hana M El Sahly
Vaccine. 2025-02-15
Press Mentions
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 27th, 2025- Memory B Cell Marker Predicts Long-Lived Antibody Response to Flu VaccineMarch 22nd, 2023
- Indians Remain Wary of Booster Doses as Covid Wanes and Side-Effect Worries RiseJanuary 17th, 2023
- Join now to see all
Grant Support
- Onco-immunologic factors contributing to OPSCC among people living with HIVUNIVERSITY OF ALABAMA AT BIRMINGHAM2024–2029
- A-Z Clinical Trials UnitUNIVERSITY OF ALABAMA AT BIRMINGHAM2007–2027
- Defining the biological relevance of HIV specific HLA-E restricted CD8 T cell responsesUNIVERSITY OF ALABAMA AT BIRMINGHAM2021–2025
- CTL And HIV Polymorphisms In Heterosexual TransmissionNational Institute Of Allergy And Infectious Diseases2010–2012
- HIV-1 Cryptic Epitopes: Implications For Vaccine DesignNational Institute Of Allergy And Infectious Diseases2009–2011
- ClinicalNational Institute Of Allergy And Infectious Diseases2008–2011
- HIV-1 Suppression By MHC Class I Restricted CD8 T CellsNational Institute Of Allergy And Infectious Diseases2007–2008
- Alabama/Zambia HIV Vaccine Clinical Trials Unit (HVTU)National Institute Of Allergy And Infectious Diseases2004–2006
- CD8+ T Cell Cytokine Production In HIV-1 InfectionNational Institute Of Allergy And Infectious Diseases2002–2005
- CD8+ T Cell Cytokine Production In HIV-1 InfectionNational Institute Of Allergy And Infectious Diseases2001
- Human Foamy Virus Structural ProteinsNational Institute Of Allergy And Infectious Diseases1996–2000
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
